Division of Surgical Oncology, Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Cancer Med. 2024 Feb;13(3):e6654. doi: 10.1002/cam4.6654. Epub 2024 Jan 17.
Black patients have higher hepatocellular carcinoma (HCC)-related mortality than White patients and more often develop HCC in non-cirrhotic liver. HCC surveillance is primarily directed toward cirrhotic patients. We aimed to characterize HCC in non-cirrhotic patients and to identify factors associated with HCC beyond Milan criteria.
Demographic, imaging, laboratory, and pathology data of HCC patients at our institution, 2003-2018, were reviewed, retrospectively. Race/ethnicity were self-reported. Cirrhosis was defined as a Fibrosis-4 score ≥3.25.
Compared to 1146 cirrhotic patients, 411 non-cirrhotic patients had larger tumors (median 4.7 cm vs. 3.1 cm, p < 0.01) and were less likely to be within Milan criteria (42.6% vs. 57.7%, p < 0.01). Among non-cirrhotic patients, Black patients had larger tumors (4.9 cm vs. 4.3 cm, p < 0.01) and a higher percentage of poorly differentiated tumors (39.4% vs. 23.1%, p = 0.02). Among cirrhotic patients, Black patients had larger tumors (3.3 cm vs. 3.0 cm, p = 0.03) and were less likely to be within Milan criteria (52.3% vs. 83.2%, p < 0.01). In multivariable analysis, lack of commercial insurance (OR 1.45 [CI 95% 1.19-1.83], p < 0.01), male sex (OR 1.34 [CI 95% 1.05-1.70], p < 0.01), absence of cirrhosis (OR 1.58 [CI 95% 1.27-1.98], p < 0.01) and Black race/ethnicity (OR 1.34 [CI 95% 1.09-1.66], p = 0.01) were associated with HCC beyond Milan criteria. Black patients had lower survival rates than other patients (p < 0.01).
Non-cirrhotic patients had more advanced HCC than cirrhotic patients. Black patients (with or without cirrhosis) had more advanced HCC than comparable non-Black patients and higher mortality rates. Improved access to healthcare (commercial insurance) may increase early diagnosis (within Milan criteria) and reduce disparities.
黑人患者的肝细胞癌(HCC)相关死亡率高于白人患者,并且更常发生于非肝硬化肝脏中的 HCC。HCC 监测主要针对肝硬化患者。我们旨在描述非肝硬化患者中的 HCC,并确定超出米兰标准的 HCC 相关因素。
回顾性分析了我们机构 2003 年至 2018 年 HCC 患者的人口统计学、影像学、实验室和病理学数据。种族/民族是自我报告的。肝硬化定义为 Fibrosis-4 评分≥3.25。
与 1146 例肝硬化患者相比,411 例非肝硬化患者的肿瘤更大(中位数 4.7cm 比 3.1cm,p<0.01),且更不符合米兰标准(42.6%比 57.7%,p<0.01)。在非肝硬化患者中,黑人患者的肿瘤更大(4.9cm 比 4.3cm,p<0.01),且中低分化肿瘤的比例更高(39.4%比 23.1%,p=0.02)。在肝硬化患者中,黑人患者的肿瘤更大(3.3cm 比 3.0cm,p=0.03),且更不符合米兰标准(52.3%比 83.2%,p<0.01)。多变量分析显示,缺乏商业保险(OR 1.45[95%CI 1.19-1.83],p<0.01)、男性(OR 1.34[95%CI 1.05-1.70],p<0.01)、无肝硬化(OR 1.58[95%CI 1.27-1.98],p<0.01)和黑人种族/民族(OR 1.34[95%CI 1.09-1.66],p=0.01)与超出米兰标准的 HCC 相关。黑人患者的生存率低于其他患者(p<0.01)。
非肝硬化患者的 HCC 比肝硬化患者更晚期。黑人患者(无论是否患有肝硬化)的 HCC 比可比的非黑人患者更晚期,死亡率更高。改善医疗保健(商业保险)的可及性可能会增加早期诊断(符合米兰标准)并减少差异。